Administer ≥2 hours before or ≥4 hours after bile acid sequestrants.Before initiation of therapy, patients should be placed on a standard cholesterol-lowering diet for 6 weeks and the diet should be continued during drug therapy.Store at 25°C (77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F). This medicine will not be as effective in lowering your cholesterol if you do not follow a cholesterol-lowering diet plan.Some cholesterol medications can cause a condition that results in the breakdown of skeletal muscle tissue, leading to kidney failure. Tablet, Oral: Zetia: 10 mg Generic: 10 mg This leads to a decreased delivery of cholesterol to the liver, reduction of hepatic cholesterol stores and an increased clearance of cholesterol from the blood; decreases total C, LDL-cholesterol (LDL-C), ApoB, and triglycerides (TG) while increasing HDL-cholesterol (HDL-C).Undergoes glucuronide conjugation in the small intestine and liver; forms metabolite (active); may undergo enterohepatic recyclingFeces (78%, 69% as ezetimibe); urine (11%, 9% as metabolite)Plasma: 4-12 hours (ezetimibe); 1-2 hours (active metabolite); Effects: ~2 weeksPlasma concentrations are approximately 2-fold higher.Plasma concentrations for total ezetimibe were slightly higher (less than 20%) in women than in men.Data from a multicenter, randomized, double-blind, placebo-controlled trial of patients with a recent acute coronary syndrome (ACS) support the addition of ezetimibe to statin therapy to reduce subsequent cardiovascular death, major coronary event (nonfatal myocardial infarction, unstable angina requiring hospitalization, or coronary revascularization within 30 days), or nonfatal stroke. This condition may be more likely to occur in older adults and in people who have kidney disease or poorly controlled hypothyroidism (underactive thyroid).It is not known whether ezetimibe alone will harm an unborn baby. Has also been shown in small pediatric trials to decrease TC and LDL-C when used as monotherapy as adjunct to dietary changes (Clauss 2009; Yeste 2009)May be administered without regard to meals. Keep using your medication as directed. Skip the missed dose if it is almost time for your next scheduled dose. Consult drug interactions database for more detailed information.• Hyperlipidemia: Secondary causes of hyperlipidemia should be ruled out prior to therapy.Adverse events were observed in some animal reproduction studies. Tell your doctor if you are pregnant or plan to become pregnant. Select one or more newsletters to continue. Fenofibrate and Derivatives may increase the serum concentration of Ezetimibe.Fibric Acid Derivatives: May enhance the adverse/toxic effect of Ezetimibe. 5: This drug is available at a higher level co-pay. Ezetimibe drug interactions (in more detail) Further information. May be taken at the same time as a statin or fenofibrate. Follow all directions on your prescription label. Do not take extra medicine to make up the missed dose.Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.Avoid eating foods that are high in fat or cholesterol. Consider discontinuation of ezetimibe and/or the statin for persistently elevated transaminases (ALT or AST ≥3 x ULN).• Myopathy: Myopathy, including rhabdomyolysis, has been reported (rarely) with ezetimibe monotherapy; risk may be increased with concomitant use of a statin or fibrate. Ezetimibe Interactions with Food and Herbs Grapefruit Juice: Ezetimibe interacts with grapefruit juice. You may report side effects to FDA at 1-800-FDA-1088.Tell your doctor about all your current medicines and any you start or stop using, especially:This list is not complete. Excipient information presented when available (limited, particularly for generics); consult specific product labeling. Discontinue ezetimibe and statin or fibrate immediately if myopathy is suspected or confirmed (symptomatic patient with CPK >10 x ULN).• Hepatic impairment: Systemic exposure is increased in hepatic impairment. Available for Android and iOS devices. Management: Avoid concomitant use of OATP1B1/1B3 substrates in patients receiving the Jynarque brand of tolvaptant.